Pain Reduction Using NEurostimulation Study

NARecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2027

Conditions
End Stage Kidney DiseaseChronic Pain
Interventions
DEVICE

Active tDCS

The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.

DEVICE

Sham tDCS

In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.

Trial Locations (2)

10021

RECRUITING

The Rogosin Institute, New York

10065

RECRUITING

NewYork-Presbyterian - Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Metropolitan Jewish Health System

OTHER

collaborator

Rogosin Institute

UNKNOWN

collaborator

Cornell University

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Weill Medical College of Cornell University

OTHER